Truist analyst David MacDonald raised the firm’s price target on Tenet Healthcare to $66 from $60 and keeps a Buy rating on the shares. The company’s Q4 results were a bit better across segments and labor showed ongoing improvement, the analyst tells investors in a research note. The firm adds that it will look for ramping ASC contribution and an additional benefit from labor as Tenet’s FY23 outlook points to "solid organic growth".
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on THC:
- Tenet Healthcare price target raised to $60 from $57 at Stephens
- Tenet Healthcare sees 2023 adjusted EPS $4.68-$5.85 vs. $7.58 in 2022
- Tenet Healthcare reports Q4 adjusted EPS $1.96 vs. $2.70 a year ago
- Tenet options imply 7.4% move in share price post-earnings
- 3 Stocks to Buy Today, 1/27/2023, According to Top Analysts